Cognition Therapeutics, Inc. (NASDAQ:CGTX) Short Interest Update
Cognition Therapeutics, Inc. experienced a significant decline in short interest in June, with a 14.2% drop from the previous month. The company's stock is currently being sold short at a rate of 0.5% and has a short-interest ratio of 1.3 days. The stock's trading volume and price have also been fluctuating. Analysts have given the stock a consensus rating of "Buy" with a price target of $8.20. Institutional investors own 43.35% of the company's stock. Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics for age-related degenerative diseases and central nervous system disorders.
Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) was the recipient of a large drop in short interest in the month of June. As of June 15th, there was short interest totalling 180,700 shares, a drop of 14.2% from the May 31st total of 210,600 shares. Approximately 0.5% of the company's shares are sold short. Based on an average trading volume of 144,300 shares, the short-interest ratio is presently 1.3 days.
Get Cognition Therapeutics alerts:
Cognition Therapeutics Price Performance
Shares of NASDAQ:CGTX traded up $0.01 during trading on Monday, reaching $1.67. 79,644 shares of the stock were exchanged, compared to its average volume of 177,680. The stock has a fifty day moving average of $2.02 and a two-hundred day moving average of $2.01. Cognition Therapeutics has a 1-year low of $0.90 and a 1-year high of $2.95. The firm has a market cap of $66.90 million, a price-to-earnings ratio of -1.82 and a beta of 1.48.
Cognition Therapeutics (NASDAQ:CGTX - Get Free Report) last released its quarterly earnings data on Tuesday, May 7th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Sell-side analysts forecast that Cognition Therapeutics will post -0.97 EPS for the current year.
Analyst Ratings Changes
Several equities research analysts recently commented on the company. B. Riley restated a "buy" rating and set a $5.00 target price on shares of Cognition Therapeutics in a research report on Thursday, March 28th. Oppenheimer reaffirmed an "outperform" rating and set a $9.00 price objective on shares of Cognition Therapeutics in a research report on Wednesday, March 27th. HC Wainwright initiated coverage on shares of Cognition Therapeutics in a research report on Wednesday, May 29th. They set a "buy" rating and a $10.00 target price on the stock. Finally, Chardan Capital assumed coverage on shares of Cognition Therapeutics in a report on Thursday, June 6th. They issued a "buy" rating and a $11.00 price target for the company. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $8.20.
Check Out Our Latest Stock Report on CGTX
Hedge Funds Weigh In On Cognition Therapeutics
Large investors have recently added to or reduced their stakes in the business. AWM Investment Company Inc. purchased a new stake in shares of Cognition Therapeutics in the first quarter worth approximately $1,183,000. Hohimer Wealth Management LLC bought a new position in Cognition Therapeutics during the 1st quarter valued at $410,000. CM Management LLC purchased a new position in Cognition Therapeutics during the 1st quarter worth $318,000. Twin Focus Capital Partners LLC bought a new stake in shares of Cognition Therapeutics in the 4th quarter worth $173,000. Finally, Texas Capital Bank Wealth Management Services Inc purchased a new stake in shares of Cognition Therapeutics in the fourth quarter valued at about $102,000. Institutional investors own 43.35% of the company's stock.
About Cognition Therapeutics
(Get Free Report)Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.
Featured Articles
- Five stocks we like better than Cognition Therapeutics
- Trading Stocks: RSI and Why it's Useful
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Trading Halts Explained
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- What is the Australian Securities Exchange (ASX)
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
→ Did Joe Biden just reveal his replacement? (From Paradigm Press) (Ad)
Should you invest $1,000 in Cognition Therapeutics right now?
Before you consider Cognition Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cognition Therapeutics wasn't on the list.
While Cognition Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
